Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval

Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval

IvelinRadkov

Sanofi (NASDAQ:SNY) and Regeneron Pharmaeuticals (NASDAQ:REGN) Dupixent (dupiliumab), already a blockbuster drug approved for several indications, including asthma and eosinophilic esophagitis, is poised for further gains as it is likely to gain approval for chronic obstructive pulmonary disease.

Dupixent sales could reach $21.4B worldwide by 2029, projects GlobalData. The therapy brought in global sales of ~$11.6B in 2023.

More on Regeneron, Sanofi

The post Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval first appeared on Investorempires.com.